Navigation Links
Aton Pharma Announces the Appointment of Dr. Fred Eshelman to Management Board

LAWRENCEVILLE, N.J., Feb. 25 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that Dr. Fred Eshelman has joined the management board of Aton's parent company, Princeton Pharma Holdings LLC. Dr. Eshelman is the founder, Vice Chairman and CEO of Pharmaceutical Product Development, Inc. (Nasdaq: PPDI), an international contract research organization. Aton is a wholly owned subsidiary of Princeton Pharma Holdings LLC.

"We are delighted that Dr. Eshelman has agreed to join Princeton Pharma Holdings' management board," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "He is a rare individual -- both an accomplished entrepreneur and an accomplished scientist. He built a very successful enterprise from the ground up and his knowledge of product development is exceptional. His insights are going to provide tremendous value to Aton as we implement our strategic plan."

"Aton is a very interesting specialty pharmaceutical company with their focus on medically essential therapeutics and I'm impressed with the amount of progress they have made in a relatively short period of time," stated Dr. Eshelman. "I look forward to lending my experience and helping this company reach its goals."

Dr. Eshelman's expertise will be helpful as Aton continues to execute its product life cycle management strategy and expand its research program, which includes partnerships with a variety of thought leaders, major medical institutions and research organizations.

Dr. Eshelman's career has included positions as Senior Vice President of Development and Vice President of Clinical Operations for the former Glaxo, Inc., as well as various roles in drug development with other pharmaceutical companies. He received his doctorate in pharmacy from the University of Cincinnati and his bachelor's degree in pharmacy from the University of North Carolina at Chapel Hill. He is a graduate of the Owner President Management (OPM) program at Harvard Business School.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under-treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see

CONTACT Ed Stevens, 727-327-3396,

SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
3. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
6. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
7. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
8. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... PHILADELPIA, PA (PRWEB) , ... November 24, 2015 , ... ... young entrepreneurs at competitive events in five states to develop and pitch their BIG ... student projects from each state are competing for votes to win the title of ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):